In a decisive move, the Senate Finance Committee recently advanced a substantial draft legislative package unanimously with a 26-0 vote. As detailed via legal news aggregator JD Supra, the progressive package in question, titled, ‘Better Mental Health Care, Lower-Cost Drugs, and Extenders Act,’ seeks to amend the roles of pharmacy benefit managers (PBMs) and enhance the focus on mental health in the medical industry.
PBMs function as intermediaries within the American healthcare system. Their main responsibility is to manage prescription drug programs on behalf of insurers, with a key focus on negotiating drug prices with pharmaceutical manufacturers. However, the proposed bill puts forward additional transparency and regulation requirements for PBMs.
The ‘Better Mental Health Care, Lower-Cost Drugs, and Extenders Act’ will require pharmacies to provide a comprehensive report on the costs of medications. This is a move designed to enhance transparency in drug pricing and may equate to lower costs for both providers and patients, a key aspect of the bill.
The Act also shifts focus towards mental health care. Although specifics are yet to be publicly disclosed, mental health might benefit from legislative attention, which could result in increased funding or stronger mandates in favor of mental health services. Importantly, this could lead to better mental health care accessibility across various demographics and income levels across the country.
Authored by Arnall Golden Gregory LLP., the timely report adds to an increasingly vital conversation about the future of American healthcare, particularly given the ongoing public health emergency.
As legal professionals working with healthcare corporations or in related practices, these legislative advancements may significantly influence the daily operation and strategic planning of your client’s or your firm’s business. Remaining abreast of this development would be beneficial for practitioners in this field.